Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 307 clinical trials
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs. Researchers want to find the highest dose of BAY2416964 that participants could take without …

  • 11 Apr, 2021
  • 20 locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have

  • 04 Apr, 2021
  • 144 locations
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

At present targeted therapy with the PARP inhibitor olaparib has become standard of care in advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the loss of homologous recombination (HR) function. The current project aims to treat patients with any type of cancer carrying in their …

  • 25 Jan, 2021
  • 1 location
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations.

  • 28 Mar, 2021
  • 21 locations
First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER)

Part A will be a dose escalation study of IV CTL002 (a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors. Part B will be a cohort expansion into up to five solid tumor indications.

  • 28 Jan, 2021
  • 5 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer. Methodology:Open label, genomic driven trial (basket trial) No. of patients total entered:Optimal Simon two stage design for the three genetic driven cohorts: 10 …

  • 22 Jan, 2021
  • 5 locations
Intervention Toward Truth-Telling and Advanced Directives in the Patient With Advanced or Metastatic Disease

Family usually had a lot of burden to tell the truth to patients. The purpose of this study is to assess the effect of education materials and family conference for advanced cancer

advanced cancer
  • 07 Nov, 2020
Hepatic Impairment Study for Lorlatinib in Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide

  • 26 Jan, 2021
  • 19 locations
Phase I Study of MOv18 IgE a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours

This first in human study of the new therapeutic antibody MOv18 IgE in patients with advanced cancer seeks to demonstrate the potential for the use of this IgE antibody as an example of the use

  • 27 Jan, 2021
  • 4 locations
A First in Human Study of BAY2701439 to Look at Safety How the Body Absorbs Distributes and Excretes the Drug and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor

  • 11 Apr, 2021
  • 3 locations